A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

Manuel Hidalgo; Jan C Buckner; Charles Erlichman; Marilyn S Pollack; Joseph P Boni; Gary Dukart; Bonnie Marshall; Lisa Speicher; Laurence Moore; Eric K Rowinsky

doi:10.1158/1078-0432.CCR-06-0118

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

Identifier:nobleid.org/w1/20260515/F0CE4F3F

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/F0CE4F3F.svg?ark=w1%2F20260515%2FF0CE4F3F)](https://nobleid.org/work/w1/20260515/F0CE4F3F)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

Identifier:nobleid.org/w1/20260515/F0CE4F3F

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/F0CE4F3F.svg?ark=w1%2F20260515%2FF0CE4F3F)](https://nobleid.org/work/w1/20260515/F0CE4F3F)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work